

Review of: "Fluoxetine plus lithium for treatment of mental health impairment in Long Covid"

Bianca Besteher¹

¹ Friedrich-Schiller Universität Jena

Potential competing interests: No potential competing interests to declare.

I really enjoyed to read the manuscript entitled "Fluoxetine plus lithium for treatment of mental health impairment in Long Covid". It is a straight forward, mechanistic line of reasoning, why fluoxetine and lithium as a low-dose combination could have a positive effect on neuropsychiatric symptoms of long-COVID. I really hope that the manuscript after some revision will be published and inform a clinical trial to test that hypothesis.

I have some minor comments:

- Please avoid the term of mental disability in the abstract. Many patients might feel even more stigmatized, if clinicians started using this term here.
- I remember that there are published case series documenting use of SSRI in general and fluoxetine in particular in long-COVID patients. Those should be cited to reinforce the idea to use antidepressants in long-COVID. And then it would be good to make the point, why the additional treatment with lithium would be beneficial. Even if side effects are unlikely in low doses, lithium and taking to pills every day still requires compliance by the patients.